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Burkholderia cepacia complex (BCC) is a group of 17 closely related bacterial species that can cause pulmonary infection in patients with
cystic ﬁbrosis (CF). The clinical manifestations of BCC infection are varied but can include cepacia syndrome, which is a rapidly progressing
necrotising pneumonia with an almost universally fatal outcome. We report the case of a 38 year old man, known to have chronic infection with the
ET12 strain of Burkholderia cenocepacia who developed cepacia syndrome 26 years after initial infection. Aggressive treatment with a
combination of 4 intravenous antibiotics, oral corticosteroids and cyclosporin brought about clinical, radiological and biochemical resolution of his
cepacia syndrome. This case highlights the possible role of cyclosporin in the treatment of cepacia syndrome.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Burkholderia cepacia complex; Cepacia syndrome; Cystic ﬁbrosis; Microbiology1. Introduction
Burkholderia cepacia complex (BCC) refers to a group of at
least 17 closely related bacterial species (formerly called
genomovars) that can cause pulmonary infection in patients with
cystic fibrosis (CF) (1,2). Although patients with CF who acquire
BCC are known to have an accelerated loss of lung function, lower
body mass index, more hospital admissions and increased
mortality, there is a wide spectrum of clinical manifestations
(3–5). This can vary from a virtually asymptomatic chronic
infection, to an acute, life threatening necrotising pneumonia
(cepacia syndrome). Individual patient outcomes are unpredictable
and probably influenced by host-pathogen interactions as well as
microbial virulence factors (6,7).
Cepacia syndrome is characterised by rapidly progressing
radiological and clinical signs of necrotising pneumonia, pyrexia
and an almost universally fatal outcome. In some cases peripheral
blood cultures are positive for BCC in the preterminal phase.⁎ Corresponding author. Tel.: +44 161 291 5007.
E-mail address: fjgilchrist@hotmail.com (F.J. Gilchrist).
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Burkholderia cenocepacia (formerly genomovar III), especially
the ET12 epidemic strain (6). There are also reports in which the
causative organism has been identified as Burkholderia cepacia
(formerly genomovar I) (8) and Burkholderia mulivorans (former-
ly genomovar II) (4,9,10). Traditionally it was thought that
cepacia syndrome occurred soon after the first isolate of BCC but
recently it has been demonstrated that it can also occur many
years after initial infection (9). BCC sepsis is also a significant
cause of mortality in patients with CF who have undergone lung
transplantation, especially in those with pre-transplant
B. cenocepacia infection. This has lead to most transplant centres
viewing chronic infection with this organism as a contraindica-
tion to transplantation (11,12). Although some authors refer to
BCC sepsis in post transplantation patients as cepacia syndrome,
as it occurs in “non-CF” lungs we have assumed that this is a
different entity for the purpose of this article.
We present the case of an adult with CFwho developed cepacia
syndrome 26 years after he initially developed chronic BCC
infection. Aggressive treatment with 4 intravenous (IV) antibiotics,
oral corticosteroids and intravenous cyclosporin resulted in
clinical, radiological and biochemical resolution of his cepacia
syndrome.by Elsevier B.V. All rights reserved.
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A38 yearmale with CF presented to the emergency department
in December 2011 with a 6 day history of high temperatures,
increased cough and increased shortness of breath. Despite daily
dornase alpha, his sputum had become thicker and was more
difficult to expectorate. He also complained of a sore throat and
reduced appetite. He had been diagnosed with cystic fibrosis (CF)
aged 4 years after an episode of distal intestinal obstruction
syndrome and was known to be homozygous Phe508del. He
became chronically infected with the ET12 strain of B.
cenocepacia aged 13 years. He transferred to the adult CF team
in 1989, aged 16 years and has been under our care since then. He
required few hospital admissions and had relatively well preserved
lung function. At the time of presentation, baseline spirometry
was: FEV1 1.95 L (49% predicted), FVC 3.65 L (75% predicted).
He did not have a totally implantable venous access device.
On examination in the emergency department he was unwell
with a temperature of 38.9 °C and oxygen saturations of 92% in
air. He was tachycardic (109/min) and hypotensive (85/53 mm
Hg). Initial investigations showed an elevated CRP (279 mg/L),
WCC (17.4×109/L) and neutrophils (15.3×109/L). Ausculta-
tion of the chest revealed bilateral coarse crackles and mild
expiratory wheeze. The chest radiograph (CXR) did not show
any significant deterioration and there was no focal consolidation
or pneumothorax (see Fig. 1A). He was too breathless to perform
spirometry. The differential diagnosis included a viral or bacterial
exacerbation and cepacia syndrome. He was commenced on 28%
oxygen, IV fluids, IV tobramycin, IV meropenem, IV co-
trimoxazole and oral prednisolone (30 mg daily). Oral oseltami-
vir was also commenced whilst an influenza PCR was awaited.
Over thenext5 days thepatient'sconditiondeterioratedwith
continuing high temperatures, large sputum volumes (up toFig. 1. Chest radiographs from acute admission and follow-up. A: day 1, B: day
4, C: day 7 and D: week 12.123 g/day) and increasing dyspnoea. He also became more
hypoxicandwascommencedonhighflowoxygen.ArepeatCXR
showed significant deterioration with bilateral multifocal
nodular consolidation (see Fig. 1B). Two sets of blood cultures
showed no bacterial growth and 2 sputum samples were negative
for a panel of 9 common respiratory viruses tested by PCR. The
patient's normal pan-resistant B. cenocepacia was isolated from
the sputum, but no other pathogens were identified. His CRP
(275 mg/L) and WCC (17.0×109) remained elevated. Given the
patient's worsening condition and the radiological changes, his
prednisolone was increased to 40 mg daily and IV chloramphen-
icol was added to his treatment regimen. Although the CF team
wanted the patient to start a nebulised antibiotic, at this stage he
was too breathless.
On day 8 the patient's clinical condition remained unchanged
but his CXR had deteriorated further with an increase in the
nodular consolidation and confluence in some areas (see Fig. 1C).
At this stage, the aggressive course of the illness in addition to the
radiological and biochemical evidence strongly suggested
cepacia syndrome and it was thought that the patient's prognosis
was very poor. It was decided that cyclosporin should be added to
his treatment regimen; he was prescribed 50 mg IV once daily for
5 days and then 50 mg orally once daily.
Over the next few weeks he improved dramatically with
hypoxia, resolution of the pyrexia, decreased sputum volume and
resolving consolidation on CXR. On day 13, after 5 days the IV
cyclosporin was changed to oral (50 mg daily). By day 21 his
prednisolone had been reduced to 20 mg daily, he was no longer
requiring oxygen and his CRP and WCC had fallen to 20 mg/L
and 13.6×109/L respectively. The consolidation seen on the
CXR was also starting to improve. The prednisolone dose was
reduced further and discontinued prior to discharge on day 35.
The IV antibiotics were also stopped on the day of discharge
At discharge his lung function was: FEV1 1.25 (31%
predicted), FVC 3.25 (67% predicted), earlobe blood gas: pH
7.46, PO2 9.3, pCO2 5.6, HCO3
− 29.4, BE 5.6, CRP 5 mg/L and
WCC 10.9×109/L. During the duration of the admission; 4 sets
of blood cultures were taken (all showed no bacterial growth), 6
sputum samples were sent for respiratory virus PCR (all were
negative) and 7 sputum samples were sent for culture (all grew
B. cenocepacia, 3 also isolated Candida albicans). Prior to
discharge he was commenced on nebulised meropenem 250 mg
BD and we plan to continue this long-term. He remains on oral
cyclosporin. A repeat CXR, 12 weeks after his initial
presentation shows complete resolution of the multifocal
nodular consolidation (see Fig. 1D).3. Discussion
To our knowledge this is the first reported case of the
successful treatment of cepacia syndrome with a combination of
IV antibiotics, oral corticosteroids and IV cyclosporin. Interest-
ingly this patient developed cepacia syndrome 26 years after he
became chronically infected. The cyclosporin was instigated
due to the patient's poor prognosis and the knowledge that of the
3 previously published cases of successful cepacia syndrome
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therapy (13–16).
The first reported case involved an 11 year old girl who was
treatedwith IVmethylprednisolone in addition to 5 IV antibiotics.
As this case was reported before the updated taxonomy of BCC
was developed, we do not know what the causative organism was
(15). The second case involved a 31 year old female infected with
B. cenocepacia (ET12 strain). She was treated with 4 IV
antibiotics, nebulised meropenem and nebulised tobramycin.
She was also receiving mycophenolate mofetil and tacrolimus as
she was 6 years post en-bloc liver–pancreas transplantation (13).
The final case involved an 8 year old girl with known
B. cenocepacia (clade A) infection. She was successfully treated
with 3 IV antibiotics, nebulised tobramycin and nebulised dornase
alpha (14). Blood cultures were positive for BCC in 2 of the 3
patients.
The role of immunosuppressant therapy in the management
of BCC sepsis in patient's post lung transplantation is also
unclear. One centre reported that between May 1988 and May
2007 they performed 61 lung transplantations in patients with
preceding B. cenocepacia ET12 strain infection. Of these, 21
developed BCC sepsis (all with positive peripheral blood
cultures) and only 2 survived. The first survivor was 9 months
post transplantation receiving tacrolimus and prednisolone, the
second was 6 years post-transplantation and receiving azathio-
prine, cyclosporine and prednisolone (16). The only factors that
the authors were able to identify that differentiated the 2 patients
that survived with the 19 others, is that the 2 patients had survived
the immediate post transplantation period and were therefore
receiving a reduced degree of immunosupression.
Cyclosporin is a calcineurin inhibitor and a potent immuno-
suppressant. Traditionally it is used for prevention of graft
rejection following organ or tissue transplantation and treatment
and prophylaxis of graft-versus-host disease, it also has a role in
the treatment of both steroid-sensitive and steroid-resistant
nephrotic syndrome. In contrast to some other immunosuppres-
sants it is virtually non-myelotoxic but is markedly nephrotoxic.
As with all similar medications it also has a wide spectrum of side
effects and interactions. Patients treated with cyclosporin need to
have their renal function, liver function, electrolytes, urate levels,
blood lipids and whole blood cyclosporin concentrations moni-
tored frequently (17).
Including the present case, 3 of the 4 reports of the successful
treatment of cepacia syndrome have used an immunosuppres-
sant. This suggests that immunomodulation may contribute to
the successful response to antibiotics by decreasing the host
response, thought to be involved in the pathogenesis of cepacia
syndrome. Given the rapidly progressing nature of cepacia
syndrome and its almost universally fatal outcome, it seems
appropriate to consider immunosuppressant therapy in addition
to aggressive treatment with IV and nebulised antibiotics. The
success of cyclosporin in this case, highlights it as one possible
agent. The long-term management of patients that survivecepacia syndrome and particularly the duration of treatment with
immunosuppressant therapy is unclear.References
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